PDA

View Full Version : Mesoblast Ltd.



  1. Here's why Mesoblast is zooming
  2. This stock is rocking
  3. Meso is Doing Its Patent Thing Now
  4. Key Pharmaceutical Executive Joins Mesoblast
  5. Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
  6. Mesoblast Reports Strong Half-Year Financial Results
  7. Key European Patent Granted for Mesoblast's MPCs
  8. Boardroom Radio Interview with Mesoblast Chief Executive
  9. Mesoblast limited Lowered to "Hold" at Morningstar (MSB)
  10. Positive Disc Repair Results Using Mesoblast Stem Cells
  11. Mesoblast limited Stock Rating Lowered by Morningstar (MSB)
  12. Stem Cell Meeting on the Mesa - Oct 2013 - Video
  13. Mesoblast limited Downgraded to "Hold" at Morningstar (MSB)
  14. 3 Companies Banking on Regenerative Medicine
  15. BREEDI : BREEDIT CORP. FILES (8-K/A) Disclosing Unregistered Sale of Equity ...
  16. Osiris Therapeutics, Inc. : Osiris Therapeutics Updates on Mesoblast Payment ...
  17. Mesoblast announces positive results from phase II trial of MPCs to treat type ...
  18. Mesoblast Reports Positive Type 2 Diabetes Trial Results
  19. Mesoblast Reports Positive Type 2 Diabetes Trial Results
  20. Mesoblast Limited (MSB.AX) Reports Positive Type 2 Diabetes Trial Results
  21. Mesoblast limited : New Japanese Regenerative Medicine Legislation
  22. Mesoblast fast tracked to enter Japanese market with their stem cell products
  23. Mesoblast limited : Scrip Award to Mesoblast for 2013 Financing Deal of the Year
  24. MPCs Strengthen Cardiac Function in End-Stage Heart Failure
  25. Chairman's Address to Shareholders
  26. Mesoblast limited : Improved Survival in Children with GvHD After Cell Therapy
  27. Mesoblast limited : MPCs Induce Functional Recovery in Ischemic Stroke Model
  28. Mesoblast limited : FDA Clears Phase 3 Heart Failure Trial
  29. FDA Clears Commencement of Phase 3 Chronic Heart Failure Trial Using Mesoblast Limited (MSB.AX)'s Proprietary Cells
  30. MESOBLAST LIMITED : Mesoblast, Intrexon and Ziopharm to Target Cancers
  31. MESOBLAST LIMITED : MSBs Registration Plans for GVHD Cell Product in Japan
  32. Mesoblast, Intrexon and Ziopharm to Target Cancers
  33. Mesoblast Limited (MSB.AX), Intrexon Corporation and ZIOPHARM Oncology, Inc. (ZIOP.OB) to Target Cancers
  34. Mesoblast limited (ADR) (MBLTY.PK): Mesoblast: Prochymal Deal Controversy ...
  35. Mesoblast limited (ADR) (MBLTY.PK): Mesoblast: Prochymal Deal Controversy ...
  36. Mesoblast limited (ADR) (MBLTY.PK): Mesoblast: Prochymal Deal Controversy ...
  37. MESOBLAST LIMITED : Mesoblast Acquires Osiris' Cultured Stem Cell Business
  38. Osiris Announces Agreement for Culture-Expanded MSCs Including Prochymal Worth Up To $100 Million Plus Royalties
  39. MESOBLAST LIMITED : Spinal Fusion Trial to be Presented at Premier Spine ...
  40. MESOBLAST LIMITED : Share Trading Policy
  41. MESOBLAST LIMITED : Share Trading Policy
  42. Strong Cash Position Enables Execution of Late-Stage Trials
  43. Strong Cash Position Enables Execution of Late-Stage Trials
  44. Midday: ASX up, gold miners shine
  45. Midday: ASX boosted by Fortescue, China PMI
  46. Midday: ASX boosted by Fortescue, China PMI
  47. Midday: ASX dips, earnings flow & dividends drag
  48. Midday: ASX dips, earnings flow & dividends drag
  49. Midday: Mixed messages freeze ASX flat
  50. Midday: Mixed messages freeze ASX flat
  51. MSB Receives $4.3M Pipeline Funds from Australian Government
  52. MSB Receives $4.3M Pipeline Funds from Australian Government
  53. Mesoblast Wins $3.9M in Australian Tax Credits Tied to Mesenchymal Precursor Cells
  54. MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
  55. MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
  56. Key Mesenchymal Precursor Cell Patent Granted in Japan
  57. MESOBLAST LIMITED : 15 May 2013 - Mesoblast's Preclinical Trial Results of ...
  58. Mesoblast Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and ...
  59. MESOBLAST LIMITED : 15 May 2013 - Mesoblast's Preclinical Trial Results of ...
  60. MESOBLAST LIMITED : 17 April 2013 – Mesoblast Appoints Renowned ...
  61. MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
  62. MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
  63. MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
  64. MESOBLAST LIMITED : 13 March 2013 - Mesoblast Completes A$170m Private ...
  65. MESOBLAST LIMITED : 13 March 2013 - Mesoblast Completes A$170m Private ...
  66. MESOBLAST LIMITED : 11 February 2013 - Mesoblast Reports Half-Year 2013 ...
  67. FDA Agree on Use of MSBs Singapore Manufacturing Facility
  68. Mesoblast Limited (ASX: MSB) (OTC ADR: MBLTY) Earnings and Development ...
  69. Mesoblast Limited (ASX: MSB) (USOTC: MBLTY) Key Mesenchymal Precursor ...
  70. Mesoblast, patents and China
  71. Mesoblast limited
  72. FDA Clears Phase 2 Clinical Trial for Rheumatoid Arthritis
  73. FDA Clears Phase 2 Clinical Trial for Rheumatoid Arthritis
  74. Positive Results in Phase 2 Lumbar Spinal Fusion Trial
  75. MESOBLAST LIMITED : 13 December 2012 - Blood Cell Expansion Trial in New ...
  76. Mesoblast Corporate Overview - CEO Message to AGM
  77. MESOBLAST LIMITED : 20 November 2012 - Mesoblast Reaches Key ...
  78. MESOBLAST LIMITED : 19 November 2012 – Market Update
  79. Mesoblast Ltd Completes Acquisition Of Angioblast Systems Inc; Announces Shares Placement; Cephalon, Inc. Acquires Shareholding In Mesoblast Ltd
  80. Nobel Winner's Stem Cells to Be Tested in Eye Malady in 2013
  81. Analyst quick to defend honour of biopharma Mesoblast
  82. Australian Stock Market Report – Midday 9/25/2012
  83. A biotech bonanza may be just hype
  84. Rexahn Reports Positive Phase 2 Data for Archexin; Dynavax Announces FDA ...
  85. World Leader in Regenerative Medicine to Be Among Companies Attending ...
  86. Cellmid appoints Graeme Kaufman as non executive director
  87. Cellmid appoints Graeme Kaufman as non executive director
  88. Mesoblast stem cell R&D spend triples
  89. Chandler Macleod posts 45pc proft rise
  90. Chandler Macleod posts 45pc proft rise
  91. Bankable asset CBA posts record profit but warns of cloudy outlook
  92. Australia's two-decade expansion at risk, McKinsey report warns
  93. Companies struggling with Facebook and Twitter backlash
  94. Health is a very good asset
  95. Commercial property values slump to lows
  96. Market big wigs face the music
  97. Country Road to take over Witchery
  98. The Short Report
  99. Midday: Aus shares 0.3% higher
  100. Midday: ASX lifts from lows on CPI
  101. RegMed sector is starting to heat up on the Hot Tin Roof
  102. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains ...
  103. Biotechs undo gains from last quarter
  104. Mesoblast Interview: The Best Adult Stem Cell Technology In The World?
  105. Australian shares flat ahead of BoE, ECB
  106. Australian shares flat ahead of BoE, ECB
  107. Outlook: ASX set to follow positive leads
  108. QRxPharma product approval hits hurdle
  109. Property performance this financial year
  110. Market Wrap: ASX up 0.7%
  111. Market Wrap: Aus shares close 0.4% lower
  112. The Short Report
  113. Midday: Aus shares fall on global fears
  114. The investor's guide to surviving a sharemarket crash
  115. The investor's guide to surviving a sharemarket crash
  116. The investor's guide to surviving a sharemarket crash
  117. NBN Co chooses Leighton, Service Stream
  118. Market Wrap: Aus shares close 1.1% lower
  119. 3 ASX stocks that beat the market yesterday
  120. Mesoblast insists Teva partnership is strong
  121. Market Wrap: ASX rises 0.4%
  122. ASX Market Wrap: ASX finishes the week on a positive note
  123. BHP lowers sights as commodity price forecasts dip in medium term
  124. The Short Report
  125. Mesoblast Provides Corporate Strategy For Product Development To Treat ...
  126. Crawling through the tape to see what's working … not much!
  127. New Teva Representative Joins Mesoblast Board of Directors
  128. FDA Petition
  129. Teva Representative Joins Mesoblast's Board of Directors
  130. New Teva Representative Joins Mesoblast Board of Directors
  131. Mesoblast limited : Msb asx new director - 10 may 2012
  132. Australian Stock Market Report – Midday 5/2/2012
  133. Australian Stock Market Report – Midday 5/2/2012
  134. Three questions to answer before the market plunges
  135. Mesoblast hits 50% enrolment for back pain trial
  136. Australian Stock Market Report – Afternoon 4/19/2012
  137. Australian Stock Market Report – Midday 4/18/2012
  138. Australian Stock Market Report – Midday 4/18/2012
  139. Intervertebral Disc Repair Phase 2 Trial Update
  140. ASX healthcare companies rebound in 2012: Acrux, ResMed, Mesoblast
  141. Athersys (ATHX) Secures New GvHD Patent for MultiStem
  142. iSonea expands board expertise with new director appointments
  143. iSonea expands board expertise with new director appointments
  144. iSonea expands board expertise with new director appointments
  145. Mesoblast Update to Credit Suisse Asia Investment Conference
  146. FDA Clears Mesoblast Ltd For Advanced Trials Of Back Pain Treatment-DJ
  147. IG Markets - Afternoon thoughts 27/2/12
  148. Half Year Results - Mesoblast Posts Strong Cash Balance
  149. Market Wrap: ASX posts third weekly loss
  150. Arizona Pain Specialists conducts pain study
  151. Mesoblast Ltd Enters Into Strategic Alliance With Lonza Group Ltd
  152. Mesoblast Ltd Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks
  153. Mesoblast Ltd Not To Pay FY 2011 Final Dividend
  154. First Minimally-Invasive Procedure Performed In Mesoblast Ltd's Phase 2 Stem Cell Trial For Lumbar Disc Repair
  155. Mesoblast Ltd Receives FDA Clearance For Phase 3 Bone Marrow Transplant Trial
  156. Mesoblast Ltd Receives FDA Approval For Bone Marrow Transplant Trial-DJ
  157. Positive Outcome from FDA Meeting
  158. Mesoblast posts successful results from diabetes stem cell trial
  159. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
  160. Mesoblast receives clearance
  161. Phase 2 Stem Cell Trial for Lumbar Disc Repair
  162. Presentation in Special Session of American Heart Association Annual Conference
  163. Mesoblast Receives FDA Clearance
  164. Mesoblast (ASX:MSB) Success in recent heart trials
  165. Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
  166. Teva buying Cephalon for $6.8 billion

Content Relevant URLs by vBSEO 3.6.0 PL2